Chemical Compound Review:
Capiibine pentylN-[1-[(2R,3R,4S,5R)- 3,4-dihydroxy-5...
Synonyms:
Caxeta, Xabine, Xeloda, Capecitabin, CAPECITABINE, ...
Bolaños,
Celio,
Manuel Hidalgo,
Johnson,
Leek,
deJonge,
Schmid,
Griffiths,
Sanderink,
Catena,
Strychor,
French,
Yoshizumi,
Russo,
Troy,
Patricia Martins,
von Gerstenberg-Helldorf,
Husseinzadeh,
Chen,
Stubbs,
Robert Pelley,
Fiveash,
Nishimura,
Fakih,
Mariani,
Schwarz,
Eskens,
Judson,
Buzzoni,
Takino,
Lenauer,
Lopez-Gómez,
Yubero,
Gattinoni,
Carter,
Blessing,
Semiond,
Lang,
Saif,
Wells Messersmith,
Richat Abbas,
ter Steeg,
Zamboni,
Ohta,
Szatrowski,
Hoff,
Antonio Jimeno,
Samid,
Hofheinz,
Fushida,
Chung,
Bertucci,
Blanquicett,
Vicent,
Cohn,
Kornek,
Ramnath,
Pazdur,
Thornton,
Fujimura,
Zamboni,
Zilembo,
Schulz,
Ratain,
Charles Erlichman,
Gnad,
Kindler,
van Oosterom,
Abbruzzese,
Depisch,
Longarini,
Miller,
Carpenter,
Lassere,
Schilsky,
Llosa,
Feliu,
Morita,
Cartwright,
Vogelzang,
Lopez,
Mannel,
Varkey,
Gómez-Reina,
Gary Croghan,
Miwa,
Cox,
Deery,
Joseph Boni,
Ninomiya,
Michelle Rudek,
Dumez,
Charles Zacharchuk,
Ricotta,
Verweij,
Javle,
Selleslach,
Kraus-Tiefenbacher,
Darcy,
Sparreboom,
Della Torre,
Sanz-Lacalle,
Bajetta,
Schüll,
Assadourian,
Creaven,
Kovats,
Leach,
Steg,
Procopio,
Willeke,
González-Baron,
Casado,
Post,
Wenz,
Ronald Bukowski,
Escudero,
Soepenberg,
Garcia,
Eloubeidi,
Hochhaus,
Lenz,
Harris,
Schneeweiss,
Hehlmann,
Diasio,
Terada,
Scheithauer,
Polito,
Raderer,
Trump,
Faithfull,
Müldner,
Ross Donehower,
Nagai,
Dan Laheru,
Repinski,
- Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. Blum, J.L., Jones, S.E., Buzdar, A.U., LoRusso, P.M., Kuter, I., Vogel, C., Osterwalder, B., Burger, H.U., Brown, C.S., Griffin, T. J. Clin. Oncol. (1999)
- Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. Hoff, P.M., Pazdur, R., Lassere, Y., Carter, S., Samid, D., Polito, D., Abbruzzese, J.L. J. Clin. Oncol. (2004)
- Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. Saif, M.W., Eloubeidi, M.A., Russo, S., Steg, A., Thornton, J., Fiveash, J., Carpenter, M., Blanquicett, C., Diasio, R.B., Johnson, M.R. J. Clin. Oncol. (2005)
- Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. Hofheinz, R.D., von Gerstenberg-Helldorf, B., Wenz, F., Gnad, U., Kraus-Tiefenbacher, U., Müldner, A., Hehlmann, R., Post, S., Hochhaus, A., Willeke, F. J. Clin. Oncol. (2005)
- Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. Cartwright, T.H., Cohn, A., Varkey, J.A., Chen, Y.M., Szatrowski, T.P., Cox, J.V., Schulz, J.J. J. Clin. Oncol. (2002)
- Implementation of capecitabine (Xeloda) into a cancer centre: UK experience. Faithfull, S., Deery, P. European journal of oncology nursing : the official journal of European Oncology Nursing Society. (2004)
- Clinical picture: leopard-like vitiligo with capecitabine. Schmid-Wendtner, M.H., Wendtner, C.M., Volkenandt, M., Heinemann, V. Lancet (2001)
- Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. Bajetta, E., Procopio, G., Celio, L., Gattinoni, L., Della Torre, S., Mariani, L., Catena, L., Ricotta, R., Longarini, R., Zilembo, N., Buzzoni, R. J. Clin. Oncol. (2005)
- Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. Feliu, J., Escudero, P., Llosa, F., Bolaños, M., Vicent, J.M., Yubero, A., Sanz-Lacalle, J.J., Lopez, R., Lopez-Gómez, L., Casado, E., Gómez-Reina, M.J., González-Baron, M. J. Clin. Oncol. (2005)
- Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors. Soepenberg, O., Dumez, H., Verweij, J., Semiond, D., deJonge, M.J., Eskens, F.A., ter Steeg, J., Selleslach, J., Assadourian, S., Sanderink, G.J., Sparreboom, A., van Oosterom, A.T. J. Clin. Oncol. (2005)
- Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. Scheithauer, W., Kornek, G.V., Raderer, M., Schüll, B., Schmid, K., Kovats, E., Schneeweiss, B., Lang, F., Lenauer, A., Depisch, D. J. Clin. Oncol. (2003)
- Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. Schilsky, R.L., Bertucci, D., Vogelzang, N.J., Kindler, H.L., Ratain, M.J. J. Clin. Oncol. (2002)
- Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Twelves, C., Glynne-Jones, R., Cassidy, J., Schüller, J., Goggin, T., Roos, B., Banken, L., Utoh, M., Weidekamm, E., Reigner, B. Clin. Cancer Res. (1999)
- Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Blanquicett, C., Saif, M.W., Buchsbaum, D.J., Eloubeidi, M., Vickers, S.M., Chhieng, D.C., Carpenter, M.D., Sellers, J.C., Russo, S., Diasio, R.B., Johnson, M.R. Clin. Cancer Res. (2005)
- Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. Camidge, R., Reigner, B., Cassidy, J., Grange, S., Abt, M., Weidekamm, E., Jodrell, D. J. Clin. Oncol. (2005)
- Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. Nadella, P., Shapiro, C., Otterson, G.A., Hauger, M., Erdal, S., Kraut, E., Clinton, S., Shah, M., Stanek, M., Monk, P., Villalona-Calero, M.A. J. Clin. Oncol. (2002)
- Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Reigner, B., Verweij, J., Dirix, L., Cassidy, J., Twelves, C., Allman, D., Weidekamm, E., Roos, B., Banken, L., Utoh, M., Osterwalder, B. Clin. Cancer Res. (1998)
- UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Carlini, L.E., Meropol, N.J., Bever, J., Andria, M.L., Hill, T., Gold, P., Rogatko, A., Wang, H., Blanchard, R.L. Clin. Cancer Res. (2005)
- Capecitabine-induced abnormalities in thyroid function tests. Narula, H.S., Carlson, H.E. Am. J. Med. (2004)
- Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Mata, J.F., García-Manteiga, J.M., Lostao, M.P., Fernández-Veledo, S., Guillén-Gómez, E., Larrayoz, I.M., Lloberas, J., Casado, F.J., Pastor-Anglada, M. Mol. Pharmacol. (2001)
- Clinical pharmacokinetics of capecitabine. Reigner, B., Blesch, K., Weidekamm, E. Clinical pharmacokinetics. (2001)
- Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum. Ninomiya, I., Terada, I., Yoshizumi, T., Takino, T., Nagai, N., Morita, A., Fushida, S., Nishimura, G., Fujimura, T., Ohta, T., Miwa, K. Int. J. Cancer (2004)
- Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889. Endo, M., Miwa, M., Eda, H., Ura, M., Tanimura, H., Ishikawa, T., Miyazaki-Nose, T., Hattori, K., Shimma, N., Yamada-Okabe, H., Ishitsuka, H. Int. J. Cancer (2003)
- Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Ishikawa, T., Sekiguchi, F., Fukase, Y., Sawada, N., Ishitsuka, H. Cancer Res. (1998)
- Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors. Fakih, M.G., Creaven, P.J., Ramnath, N., Trump, D., Javle, M., Strychor, S., Repinski, T.V., Zamboni, B.A., Schwarz, J.K., French, R.A., Zamboni, W.C. Clin. Cancer Res. (2005)
- Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy. Chung, Y.L., Troy, H., Judson, I.R., Leek, R., Leach, M.O., Stubbs, M., Harris, A.L., Griffiths, J.R. Clin. Cancer Res. (2004)
- A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. Laheru, D., Croghan, G., Bukowski, R., Rudek, M., Messersmith, W., Erlichman, C., Pelley, R., Jimeno, A., Donehower, R., Boni, J., Abbas, R., Martins, P., Zacharchuk, C., Hidalgo, M. Clin. Cancer Res. (2008)
- Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome. Grunda, J.M., Fiveash, J., Palmer, C.A., Cantor, A., Fathallah-Shaykh, H.M., Nabors, L.B., Johnson, M.R. Clin. Cancer Res. (2010)
- Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults. Patel, A., Pluim, T., Helms, A., Bauer, A., Tuttle, R.M., Francis, G.L. Cancer Chemother. Pharmacol. (2004)
- Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study. Garcia, A.A., Blessing, J.A., Lenz, H.J., Darcy, K.M., Mannel, R.S., Miller, D.S., Husseinzadeh, N. Gynecol. Oncol. (2005)
- Hydrolysis of capecitabine to 5'-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. Quinney, S.K., Sanghani, S.P., Davis, W.I., Hurley, T.D., Sun, Z., Murry, D.J., Bosron, W.F. J. Pharmacol. Exp. Ther. (2005)
- Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Deenen, M.J., Tol, J., Burylo, A.M., Doodeman, V.D., de Boer, A., Vincent, A., Guchelaar, H.J., Smits, P.H., Beijnen, J.H., Punt, C.J., Schellens, J.H., Cats, A. Clin. Cancer Res. (2011)
- Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. Dunst, J., Reese, T., Sutter, T., Zühlke, H., Hinke, A., Kölling-Schlebusch, K., Frings, S. J. Clin. Oncol. (2002)